Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. 2017

Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
National Institute of Mental Health, Klecany, Czech Republic.

OBJECTIVE It has been well established that long-term antipsychotic treatment prevents relapse, lowers number of rehospitalisations, and also effectively reduces violent behaviour. Although violent behaviour is not a typical manifestation of schizophrenia or other psychotic disorders, the diagnosis of psychosis increases the overall risk of violence. One of the few modifiable factors of violence risk is adherence with medication. In contrast, non-adherence with drug treatment and subsequent relapse increases risk of violent acts. Non-adherence can be addressed partially by long-acting injectable antipsychotics (LAI). The aim of our review was to examine the role of antipsychotic drugs, especially LAI, in prevention and management of violent behaviour in psychosis. METHODS This is a non-systematic, narrative review of the data from open, naturalistic, retrospective, and population studies, case series, and post hoc analyses of randomised controlled trials. Search of electronic databases (PubMed, Embase) was performed to identify relevant papers. RESULTS Nine published papers (3 cross-sectional chart reviews, 4 retrospective studies, 2 prospective, randomised trials) were found. The results indicated positive clinical and antiaggressive effects of LAI in psychotic patients with high risk of violent behaviour. CONCLUSIONS Reviewed evidence suggests that secured drug treatment with LAI may have clinical benefit in schizophrenia patients with high risk of violent behaviour. LAI significantly reduced the severity of hostility, aggressivity, number of violent incidents, and criminal offences. These findings are supported further by the empirical evidence from clinical practice, high rates of prescribed LAI to schizophrenia patients in high-security and forensic psychiatric facilities. CONCLUSIONS Available data encourage the use of LAI in forensic psychiatry, especially during court-ordered commitment treatment.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000374 Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism. Aggressions
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D012565 Schizophrenic Psychology Study of mental processes and behavior of schizophrenics. Psychology, Schizophrenic
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D014754 Violence Use of physical force causing or intent to cause harm, injury or abuse. Assaultive Behavior,Atrocities,Behavior, Assaultive,Interpersonal Violence,Physical Assault,Physical Attacks,Structural Violence,Violent Crime,Assault, Physical,Attack, Physical,Attacks, Physical,Crime, Violent,Interpersonal Violences,Physical Assaults,Physical Attack,Violence, Interpersonal,Violence, Structural,Violent Crimes
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
September 2019, International journal of psychiatry in clinical practice,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
November 2019, Journal of psychosocial nursing and mental health services,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
July 2019, Harefuah,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
May 2013, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
November 2015, The Medical letter on drugs and therapeutics,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
July 2021, The lancet. Psychiatry,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
February 2017, Journal of child and adolescent psychopharmacology,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
January 2023, Journal of clinical psychopharmacology,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
July 1967, Diseases of the nervous system,
Pavel Mohr, and Pavel Knytl, and Veronika Voráčková, and Anna Bravermanová, and Tomáš Melicher
September 2017, Psychiatria Danubina,
Copied contents to your clipboard!